Median Technologies to Participate in the TD Cowen’s 44th Annual Health Care Conference
2024年3月1日 - 1:45AM
ビジネスワイヤ(英語)
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible)
(Paris:ALMDT), will be participating in the TD Cowen’s 44th Annual
Health Care Conference, taking place on March 4 – 6 ,2024, at the
Boston Marriott Copley Place in Boston, MA, USA.
Fredrik Brag, Median’s CEO and Founder will present on March 6th
at 2:50-3:20 pm ET (8:50 pm CET).
The live presentation will be available here and the replay will
be posted on Median Technologies’ website, Investors section.
TD Cowen’s 44th Annual Health Care Conference is taking place
March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA. The
conference incorporates presentations, fireside chats and
innovative panel discussions, hosted by members of the TD Cowen
research team, that focus on various aspects of the Health Care
industry.
About TD Cowen: As a leading corporate and investment
bank, TD Securities offers a wide range of integrated capital
markets products and services. Our corporate, government, and
institutional clients choose us for our innovation, execution, and
experience. With more than 6,500 professionals operating out of 40
cities across the globe, we help clients meet their needs today and
prepare for tomorrow. Our services include underwriting and
distributing new issues, providing trusted advice and
industry-leading insight, extending access to global markets, and
delivering integrated transaction banking solutions. TD
Cowen is a division of TD Securities. As part of TD Securities'
broader suite of integrated capital markets products and services,
our offering includes investment banking, research, sales and
trading, prime brokerage, outsourced trading, and commission
management services. We are growth-oriented, people-focused, and
community-minded. As a team, we work to deliver value for our
clients every day.
About Median Technologies: Pioneering in innovative imaging
solutions and services, Median Technologies harnesses cutting-edge
AI to elevate the accuracy of early cancer and metabolic disease
diagnoses and treatments. Median's offerings, including iCRO for
medical image analysis and management in oncology trials and
eyonis™, AI/ML tech-based suite of software as medical devices
(SaMD), empower biopharmaceutical entities and clinicians to
advance patient care and expedite novel therapies. Since its
inception, the French-based company, with a presence in the U.S.
and China, has been recognized as an "Innovative company" by BPI
France and trades on the Euronext Growth market (ISIN:
FR0011049824, ticker: ALMDT). Median is eligible for the French SME
equity savings plan scheme (PEA-PME). For more information:
www.mediantechnologies.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229807079/en/
Median Technologies Emmanuelle Leygues Head of Corporate
Marketing & Financial Communications +33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59
median@alizerp.com
Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49
24 ghislaine.gasparetto@seitosei-actifin.com
Median Technologies (EU:ALMDT)
過去 株価チャート
から 4 2024 まで 5 2024
Median Technologies (EU:ALMDT)
過去 株価チャート
から 5 2023 まで 5 2024